Vancomycin-resistant Staphylococcus aureus: Difference between revisions

	Vancomycin-resistant Staphylococcus aureus Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Vancomycin-resistant Staphylococcus aureus On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Vancomycin-resistant Staphylococcus aureus All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Vancomycin-resistant Staphylococcus aureus
CDC on Vancomycin-resistant Staphylococcus aureus
Vancomycin-resistant Staphylococcus aureus in the news
Blogs on Vancomycin-resistant Staphylococcus aureus
Directions to Hospitals Treating Vancomycin-resistant Staphylococcus aureus
Risk calculators and risk factors for Vancomycin-resistant Staphylococcus aureus

Revision as of 16:05, 17 December 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

^ Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7. PMID 12672861.

@@ Line 34: / Line 34: @@
 http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_labFAQ.html
-== Treatment ==
-VISA and VRSA cannot be successfully treated with vancomycin because these organisms are no longer susceptibile to vancomycin. However, to date, all VISA and VRSA isolates have been susceptible to other Food and Drug Administration (FDA) approved drugs.
 === Pharmacotherapy ===
@@ Line 42: / Line 40: @@
 http://www.cdc.gov/ncidod/dhqp/ar_visavrsa.html
-=== Primary Prevention ===
-Use of appropriate infection control practices (such as wearing gloves before and after contact with infectious body substances and adherence to hand hygiene) by healthcare personnel can reduce the spread of VISA and VRSA.
 ===== References =====
 http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_FAQ.html#3
-=== Secondary Prevention ===
-Because VISA and VRSA are only part of the larger problem of antimicrobial resistance in healthcare settings, CDC has started a Campaign to Prevent Antimicrobial Resistance. The campaign centers around four strategies that clinicians can use to prevent antimicrobial resistance: prevent infections; diagnose and treat infections effectively; use antimicrobials wisely; and prevent transmission. A series of evidence-based steps are described that can reduce the development and spread of resistant organisms such as VISA and VRSA.
 ===== References =====
 http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_FAQ.html#3
 ==Additional Resources==